OPK on Nasdaq

Opko Health Inc.

Logo: opko.com4

Medical test and medication company

OPKO Health, Inc. is a medical test and medication company focused on diagnostics and pharmaceuticals.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 18, 2026.

Overview

1991Founded1

Compare with INSMED Inc, TG Therapeutics or Catalyst Pharmaceuticals, or pick any stock.

  • TickerOPK on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersMiami1
  • Founded inUnited States1
  • Websitewww.opko.com
  • Legal formlimited company1
  • Listed onNasdaq (OPK), Tel Aviv Stock Exchange (OPK)1
  • Incorporated inDE5
  • Business address4400 Biscayne Blvd., Miami, Fl 331375
  • Filer categoryAccelerated filer5

See how the biggest companies compare on our leaderboards

Opko Health Inc. image from its website
Image: opko.com4

OPKO Health, Inc. is a medical test and medication company focused on diagnostics and pharmaceuticals. The company is a publicly traded company on NASDAQ and TASE under the symbol "OPK".3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

33.9%Gross margin7
-19.3%Operating margin7
-37.2%Net margin7
-14.9%Revenue growth, 20257
-17.8%Return on equity7
0.00×Debt to equity7

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Service brought in 56% of the revenue Opko Health Inc. broke down this way in fiscal 2025.

  1. Service$370.3M756%down 23% from 2024
  2. Product$156.9M724%up 1% from 2024
  3. Transfer of Intellectual Property and Other$79.7M712%up 3% from 2024
  4. Rayaldee$59.4M79%down 14% from 2024
Products and services by year
Products and services202320242025
Service$515.3M$480.7M$370.3M
Product$167.6M$155.1M$156.9M
Transfer of Intellectual Property and Other$180.7M$77.4M$79.7M
Rayaldee$67.5M$69.3M$59.4M

Regions

United States brought in 72% of the revenue Opko Health Inc. broke down this way in fiscal 2025.

  1. United States$436.1M772%down 20% from 2024
  2. CL$62.4M710%down 4% from 2024
  3. I E$51.4M78%up 6% from 2024
  4. Spain$26.7M74%up 8% from 2024
  5. Mexico$25.5M74%up 7% from 2024
  6. Other Countries$4.3M71%up 37% from 2024
  7. Israel$522.0K70%down 71% from 2024
Regions by year
Regions202320242025
United States$597.8M$546.3M$436.1M
CL$68.5M$65.0M$62.4M
I E$141.5M$48.4M$51.4M
Spain$23.5M$24.6M$26.7M
Mexico$20.2M$23.9M$25.5M
Other Countries$2.2M$3.1M$4.3M
Israel$9.7M$1.8M$522.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue53¢$400.9M
  • Research and development16¢$124.0M
  • Selling, general and admin29¢$223.0M
  • Income tax2¢$15.7M

Out of $606.9M in revenue.7 The company lost money this year.

Financial statements

Revenue8910117$606.9M in 2025−33% since 2019
0$500.0M$1.0B$1.5B$2.0B2019: $901.9M$901.9M20192020: $1.4B$1.4B2020+59%2021: $1.8B$1.8B2021+24%2022: $1.0B$1.0B2022−43%2023: $863.5M$863.5M2023−14%2024: $713.1M$713.1M2024−17%2025: $606.9M$606.9M2025−15%
Gross profit117$205.9M in 2025−29% since 2022
0$100.0M$200.0M$300.0M$400.0M2022: $288.2M$288.2M20222023: $318.1M$318.1M2023+10%2024: $218.5M$218.5M2024−31%2025: $205.9M$205.9M2025−6%
Operating income8910117-$117.4M in 2025−57% since 2019
-$300.0M-$200.0M-$100.0M0$100.0M2019: -$274.1M-$274.1M20192020: $57.7M$57.7M20202021: $18.8M$18.8M2021−68%2022: -$226.3M-$226.3M20222023: -$157.0M-$157.0M2023−31%2024: -$152.1M-$152.1M2024−3%2025: -$117.4M-$117.4M2025−23%
Net income8910117-$225.7M in 2025−28% since 2019
-$400.0M-$300.0M-$200.0M-$100.0M0$100.0M2019: -$314.9M-$314.9M20192020: $30.6M$30.6M20202021: -$30.1M-$30.1M20212022: -$328.4M-$328.4M2022+989%2023: -$188.9M-$188.9M2023−42%2024: -$53.2M-$53.2M2024−72%2025: -$225.7M-$225.7M2025+324%

Every line of the income statement as filed: the last 3 fiscal years (annual) or 8 quarters (quarterly), latest first.7

Period ending2025-12-312024-12-312023-12-31
Revenues$606.9M$713.1M$863.5M
Cost of Goods and Services Sold$400.9M$494.6M$545.4M
Selling, general and administrative$223.0M$304.2M$300.6M
Research and development$124.0M$105.2M$89.6M
Contingent consideration$0$0-$1.0M
Amortization of intangible assets$77.9M$82.6M$86.0M
Gain on sale of assets-$101.6M-$121.5M$0
Total costs and expenses$724.3M$865.2M$1.0B
Operating loss-$117.4M-$152.1M-$157.0M
Interest income$14.8M$8.4M$4.0M
Interest expense-$108.5M-$47.5M-$13.5M
Fair value changes of derivative instruments, net-$429.0K-$26.2M-$781.0K
Other income (expense), net-$29.9M$206.9M-$17.0M
Other income (expense), net-$124.0M$141.7M-$27.3M
Loss before income taxes and investment losses-$241.4M-$10.4M-$184.3M
Income tax benefit (provision)$15.7M-$42.8M-$4.4M
Net loss before investment losses-$225.7M-$53.2M-$188.8M
Loss from investments in investees-$29.0K-$18.0K-$107.0K
Net loss-$225.7M-$53.2M-$188.9M
Loss per share Basic-$0.30-$0.08-$0.25
Loss per share diluted-$0.30-$0.08-$0.25
Weighted average number of common shares outstanding, basic751.1M shares694.0M shares751.8M shares
Weighted average number of common shares outstanding, diluted751.1M shares694.0M shares751.8M shares

Compare Opko Health Inc. with another company

The story

OPKO Health is a diversified healthcare company present in more than 30 countries. The company's primary businesses include

Bioreference Laboratories, a clinical laboratory with a core genetic testing business

The 4K Test Score, a blood test for prostate cancer

Pharmaceutical development, with products such as Rayaldee

Varubi, a chemotherapy inducted nausea medication

As of 2024, the chairman and CEO of OPKO is Phillip Frost.

In May 2022, OPKO Health announced the acquisition for $300 million of U.S. based Biotechnology firm, ModeX. With it OPKO gained proprietary immunotherapy technology for infectious diseases and oncology.

From Wikipedia’s article on OPKO Health, shared under CC BY-SA 4.0.6

Leadership

Who has led Opko Health Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. John A. Paganelli2006
  2. Phillip Et Al Frost Md.2007–now

Chair

  1. Phillip Et Al Frost Md.2007–now

President

  1. Dale R. Pfost2007
  2. Elias A. Zerhouni2022–now

Chief financial officer

  1. Subbarao Uppaluri V.2007–2011
  2. Juan F. Rodriguez2012
  3. Adam Logal2014–now
1995200020052010201520202025
Board members and other officers (31)

Former names

  • EXEGENICS INCMay 5, 2004 to Jun 13, 20075
  • CYTOCLONAL PHARMACEUTICS INC /DESep 10, 1996 to Jun 4, 20015

Timeline

  1. Mar 30, 2007New chief executive Phillip Et Al Frost Md. becomes CEO16
  2. Apr 11, 2006New chief executive John A. Paganelli becomes CEO17
  3. 1991Founded Founded in United States1

Filings

291 filings to the SEC since October 2021: 7 annual reports, 17 quarterly reports, 59 major events, 166 insider forms, 23 large holders, 19 other. The latest 20:

  1. Oct 15, 20268-K EDGAR
  2. Oct 2, 20268-K EDGAR
  3. Aug 28, 202610-Q/A EDGAR
  4. Aug 28, 202610-Q/A EDGAR
  5. Aug 14, 20268-K EDGAR
  6. Jul 28, 20264 EDGAR
  7. Jul 28, 20264 EDGAR
  8. Jul 27, 202610-Q EDGAR
  9. Jul 27, 20268-K EDGAR
  10. Jul 1, 2026SCHEDULE 13D/A EDGAR
  11. Jun 22, 20264 EDGAR
  12. Jun 22, 20264 EDGAR
  13. Jun 22, 20264 EDGAR
  14. Jun 22, 20264 EDGAR
  15. Jun 22, 20264 EDGAR
  16. Jun 22, 20264 EDGAR
  17. Jun 18, 20268-K EDGAR
  18. May 15, 2026DEFA14A EDGAR
  19. Apr 30, 2026ARS EDGAR
  20. Apr 30, 2026DEFA14A EDGAR

The 291 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 23 such filings since October 2021, the latest 10:

  1. Jul 1, 2026SCHEDULE 13D/A
  2. Oct 1, 2025SCHEDULE 13D/A
  3. Jul 9, 2025SCHEDULE 13G/A
  4. Apr 3, 2025SCHEDULE 13D/A
  5. Apr 3, 2025SCHEDULE 13D/A
  6. Nov 15, 2024SC 13D/A
  7. Nov 13, 2024SC 13G
  8. Nov 12, 2024SC 13G/A
  9. Nov 4, 2024SC 13G/A
  10. Aug 29, 2024SC 13D/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Rubric Capital Management LP47,791,243$71.7M0.7%No change
BlackRock, Inc.36,978,893$55.5M0.0%+746,670
Vanguard Capital Management LLC14,968,930$22.5M0.0%+469,766
Vanguard Portfolio Management LLC14,934,924$22.4M0.0%+165,205
Geode Capital Management, LLC11,581,027$17.4M0.0%+279,526
State Street Corp10,309,070$15.5M0.0%+807,693
Goldman Sachs Group Inc7,035,492$10.6M0.0%−639,534
UBS Group AG5,006,284$7.5M0.0%−1,065,148
Whitefort Capital Management, LP4,511,412$6.8M1.7%+258,072
Northern Trust Corp3,756,163$5.6M0.0%+136,817
Highbridge Capital Management LLC3,593,925$5.4M0.3%New
Charles Schwab Investment Management Inc3,596,980$5.4M0.0%+22,941
Vanguard Fiduciary Trust Co2,706,235$4.1M0.0%−35,782
AWM Investment Company, Inc.2,110,000$3.2M0.3%+10,000
Morgan Stanley1,975,027$3.0M0.0%+778,940
Citadel Advisors LLC1,420,922$2.1M0.0%−658,625
Washington Growth Strategies LLC1,356,124$2.0M1.1%No change
Bank of New York Mellon Corp1,329,974$2.0M0.0%+49,932
Dimensional Fund Advisors LP1,267,741$1.9M0.0%−292,259
Y.D. More Investments Ltd1,257,568$1.9M0.1%−41,905
Aqr Capital Management LLC1,239,399$1.9M0.0%+475,809
OP Asset Management Ltd1,159,647$1.7M0.0%+57,393
Voya Investment Management LLC1,094,111$1.6M0.0%−66,816
California State Teachers Retirement System961,484$1.4M0.0%+547,447
Clearstead Advisors, LLC883,288$1.3M0.0%−831

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
    Company websiteOpko Health Inc. logo
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49